The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab-Reference-Cited by-同舟云学术

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

Published:2019-08-19 Issue:1 Volume:34 Page:296-300
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kreuzer Karl-Anton,Furman Richard R.,Stilgenbauer Stephan,Dubowy Ronald L.,Kim Yeonhee,Munugalavadla Veerendra,Lilienweiss Esther,Reinhardt Hans Christian,Cramer Paula,Eichhorst Barbara,Hillmen Peter,O’Brien Susan M.,Pettitt Andrew R.,Hallek Michael

Funder

Gilead Sciences

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0533-6.pdf

Reference15 articles.

1. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia. 2009;23:117–24.

2. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.

3. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177–84.